Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,183 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Intravenous saline Clear all
Active, not recruiting Phase 1Phase 2 Interventional

Autologous Bone Marrow Aspirate (IV) and Bone Marrow Concentrate (Intranasal) for Parkinson's Disease and Parkinson-Plus Syndromes (SPARC-PD)

NCT07751640
View directory record Official record
Conditions
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
Interventions
Autologous Bone Marrow Aspirate (BMA) and Bone Marrow Aspirate Concentrate (BMAC)
Biological
Lead sponsor
Apeiron Research Center
Other
Eligibility
40 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 3, 2026, 2:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein

NCT05274568
View directory record Official record
Conditions
Parkinson Disease, Multisystem Atrophy, Healthy Volunteer
Interventions
[18F]UCB-2897
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 3, 2026, 2:00 PM EDT
Recruiting Phase 3 Interventional

Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep (MINDDS II)

NCT06192615
View directory record Official record
Conditions
Delirium
Interventions
Intravenous Dexmedetomidine, Sublingual Dexmedetomidine, Intravenous Placebo, Sublingual Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 3, 2026, 2:00 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy

NCT05612178
View directory record Official record
Conditions
HIV-1
Interventions
3BNC117-LS, 10-1074-LS, Sterile Saline
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 3, 2026, 2:00 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Intravenous Iron Effects on Performance at High Altitude

NCT06686693
View directory record Official record
Conditions
Hypoxia
Interventions
Injectafer, Placebo
Drug · Other
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 3, 2026, 2:00 PM EDT
Recruiting Phase 2 Interventional

Motivation for IV Alcohol Self-Administration in Humans

NCT06494891
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Intravenous Alcohol
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 3, 2026, 2:00 PM EDT
Completed Phase 3 Interventional Results available

Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)

NCT04317040
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
Efprezimod alfa, Placebo
Drug
Lead sponsor
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
10
States / cities
Jacksonville, Florida • Annapolis, Maryland • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 3, 2026, 2:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects

NCT05226923
View directory record Official record
Conditions
Bacterial Infections
Interventions
KSP-1007, Placebo:0.9% sodium chloride, Meropenem
Drug · Other
Lead sponsor
Sumitovant Biopharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Sep 3, 2026, 2:00 PM EDT
Completed Phase 4 Interventional Results available

Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study

NCT02806024
View directory record Official record
Conditions
Placenta Accreta, Postpartum Hemorrhage, Cesarean Section, Tranexamic Acid
Interventions
Tranexamic Acid, Placebo Drug
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Sep 3, 2026, 2:00 PM EDT
Terminated Phase 4 Interventional Results available

Angiotensin II for Distributive Shock

NCT04904562
View directory record Official record
Conditions
Distributive Shock
Interventions
Angiotensin II, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 3, 2026, 2:00 PM EDT
Completed Phase 3 Interventional Results available

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)

NCT00409188
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo
Biological · Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
1,513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
49
States / cities
Fort Smith, Arkansas • Anaheim, California • Glendale, California + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Sep 3, 2026, 2:00 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

NCT03924869
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Placebo
Radiation · Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
42
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 3, 2026, 2:00 PM EDT
Completed Not applicable Interventional Results available

Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage

NCT00606905
View directory record Official record
Conditions
Miscarriage, Recurrent, Abortion, Habitual
Interventions
Gamimune N or Gamunex 10%, normal saline
Biological · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2012 · Synced Sep 3, 2026, 2:00 PM EDT
Completed Not applicable Interventional Results available

The Effect of Tight Glycemic Control on Surgical Site Infection Rates in Patients Undergoing Open Heart Surgery

NCT01831154
View directory record Official record
Conditions
Diabetes, Hyperglycemia, Surgical Site Infection
Interventions
Tight Glycemic, Conventional Glycemic, Standard Glycemic
Drug
Lead sponsor
James A. Haley Veterans Administration Hospital
Federal
Eligibility
21 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 23, 2017 · Synced Sep 3, 2026, 2:00 PM EDT
Completed Early Phase 1 Interventional

Ketamine for MS Fatigue

NCT06064162
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ketamine
Drug
Lead sponsor
Alta Bates Summit Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Sep 3, 2026, 2:00 PM EDT
Completed Phase 2 Interventional Results available

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

NCT02734862
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis
Interventions
CD101, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Davis, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 3, 2026, 2:00 PM EDT
Completed Phase 1 Interventional

A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease

NCT01966666
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
TPI-287 2 mg/m2, TPI-287 6.3 mg/m2, TPI-287 20 mg/m2, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 82 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Sep 3, 2026, 2:00 PM EDT
Withdrawn Not applicable Interventional

Intravenous Lidocaine and Quality of Recovery After Cesarean Delivery

NCT02257346
View directory record Official record
Conditions
Pregnancy
Interventions
Lidocaine, Normal Saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 3, 2026, 2:00 PM EDT
Completed Phase 2 Interventional Results available

Arginine Therapy for Sickle Cell Disease Pain

NCT02536170
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Pain Episode
Interventions
L-arginine, L-arginine Loading Dose, Placebo
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
3 Years to 21 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 3, 2026, 2:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nitrous Oxide Versus Intravenous Sedation for Anesthesia

NCT02755090
View directory record Official record
Conditions
Pregnancy Termination in Second Trimester
Interventions
Nitrous Oxide, IV Saline
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Denver, Colorado • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Sep 3, 2026, 2:00 PM EDT
Completed Phase 2 Interventional Results available

Single Dose of Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis

NCT02469597
View directory record Official record
Conditions
Bronchiolitis
Interventions
Furosemide, Placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
Up to 48 Months
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Sep 3, 2026, 2:00 PM EDT
Terminated Phase 1 Interventional

Study of Satraplatin (JM-216) in Combination With Docetaxel

NCT00125411
View directory record Official record
Conditions
Tumors
Interventions
satraplatin and docetaxel
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 25, 2012 · Synced Sep 3, 2026, 2:00 PM EDT
Active, not recruiting Phase 2 Interventional

Study of JK07 in Patients With Chronic Heart Failure

NCT06369298
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Interventions
JK07, Placebo
Drug
Lead sponsor
Salubris Biotherapeutics Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
51
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 3, 2026, 2:00 PM EDT
Completed Phase 4 Interventional Results available

Intravenous Fluids in Benign Headaches Trial

NCT03185130
View directory record Official record
Conditions
Headache
Interventions
Normal Saline 5mL, Normal Saline 20mL/kg, Prochlorperazine 0.15 mg/kg up to 10 mg IV, Diphenhydramine 1 mg/kg up to 50 mg IV
Drug
Lead sponsor
University Medical Center of Southern Nevada
Other
Eligibility
10 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Sep 3, 2026, 2:00 PM EDT